According to TipRanks.com, Fein is a 5-star analyst with an average return of 19.8% and a 56.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Global Blood Therapeutics.
Epizyme has an analyst consensus of Moderate Buy, with a price target consensus of $18.00, implying an 84.0% upside from current levels. In a report issued on February 24, Citigroup also maintained a Buy rating on the stock with a $27.00 price target.
See today’s analyst top recommended stocks >>
Based on Epizyme’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $8.38 million and GAAP net loss of $66.23 million. In comparison, last year the company earned revenue of $4.29 million and had a GAAP net loss of $56.4 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.